Compare Five Below Inc (FIVE) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs McKesson Corporation — how do they compare? Five Below Inc trades at $209.84 (market cap $11.55B), while McKesson Corporation trades at $935.88 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 9.4× Five Below Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and McKesson Corporation for 74 Days on average.
| FIVE | MCK | |
|---|---|---|
Market Cap | $11.55B | $108.46B |
Volume | 1,120,554 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $995.69 |
52-Week Low | $138.49 | $725.17 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | $12.40B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $204.24, down 2.71% today, with strong analyst support (60% buy ratings) and a consensus price target of $298.44. The stock shows robust fundamentals with revenue growth from $3.6B in 2024 to $3.9B in 2025 and projected $5.3B in 2026, alongside consistent earnings beats. Technical indicators are mixed with a bearish overall signal but bullish oscillators, while recent news highlights digital marketing initiatives and board appointments.
FIVE presents a compelling growth story with raised 2026 guidance and strong profitability metrics (ROE 28.25%), though premium valuation (P/E 18.81) and execution risks amid consumer spending pressures warrant caution. Upside potential exists if traffic and margin trends sustain, but investors should monitor inflation impacts on discretionary retail spending.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
